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Abstract
The purpose of this study was to quantify the free-circu‐
lating plasma HER-2 DNA (cfHER-2 DNA) and to assess
the ability of analysis to discriminate between patients with
primary breast cancer and healthy controls in order to
detect metastatic recurrence in comparison with serum
HER-2 protein and also HER-2 gene amplification.
The study population consisted of 100 patients with
primary breast cancer and 50 healthy female donors. An
additional 22 patients with metastases were subsequently
included. cfHER-2 DNA was quantified with a quantitative
PCR method together with a reference gene.
Results: Using a cut-off of 2.5 for the ratio of the cfHER-2
DNA/reference gene, three (of 15) tissue HER-2-positive
patients had a ratio >2.5 prior to the detection of metastatic
disease. In the post-metastatic/pre-chemotherapy setting,
11 (of 23) tissue HER-2-positive patients with metastases
had a ratio >2.5.
There was no difference between absolute preoperative
cfHER-2 DNA values for patients with primary breast
cancer and those for healthy controls. There was no
difference between cfHER-2 DNA values taken within nine
months of development of the metastatic disease and the
levels in patients without metastases, but there was a
significant difference in the corresponding serum HER-2
protein levels in the tissue HER-2-positive patient group.
Conclusion: Amplified HER-2 DNA can be detected in
plasma when using a ratio between cfHER-2 DNA and a
reference gene. cfHER-2 DNA could not be used to dis‐
criminate between patients with primary breast cancer and
healthy controls, and could not predict the development of
metastatic disease.
Keywords breast cancer, cell-free DNA, gene amplifica‐
tion, HER-2, metastatic recurrence, sensitivity
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1. Introduction
Breast cancer is the most common cancer in women in the
Western world. Although significant progress has been
made in the adjuvant treatment of primary breast cancer,
more than 20% of patients initially diagnosed with regional
disease develop systemic relapse later in life [1]. This
implies the need for biomarkers for evaluating the effect of
treatment after primary therapy and also for early recur‐
rence detection.
The presence of increased free-circulating DNA in serum
from cancer patients was described more than 30 years ago
[2]. Subsequent studies reported increased levels of free-
circulating DNA in plasma/serum from patients affected by
colon and lung cancer [3].
The source of the free-circulating DNA is still a debated
subject. In healthy people it has been stated to originate
from the apoptosis of nucleate cells [4], but some consider
it to also originate from active release [5;6]. In cancer
patients, an increased level is hypothesized to originate
from the necrosis of cancer cells, and perhaps also from
active release from cancer cells [7]. Another hypothesis is a
possible perturbation of the mechanism of DNA clearance
from plasma, which is also unconfirmed [5].
Quantification of HER-2 gene-copy number in the circulat‐
ing cell-free DNA is a novel suggested biomarker to detect
possible amplification. Recent studies have investigated its
potential for detecting HER-2 amplification in plasma [8]
and also for monitoring response to Trastuzumab treat‐
ment [9].
The purpose of this study is to quantify the free-circulating
plasma HER-2 DNA. For this purpose a quantitative
method for detecting plasma HER-2 gene-copy number in
the total free-circulating DNA was developed and validat‐
ed. The study focuses on the ability of the analysis to
discriminate between patients with primary breast cancer
and healthy controls, as well as to detect metastatic
recurrence and establish correlation to tissue HER-2 status
and serum HER-2 protein.
2. Methods
2.1 Study Design and Population
This study was performed on plasma samples from a
previous prospective project, which was carried out on
breast cancer patients in the period 2004–2009. The moni‐
toring time had a range of 1.1–6.3 years (mean 3.6). The
patients were primarily and prospectively monitored with
serum HER-2 protein; the total population is described in
a previous article [10]. Both plasma and serum samples
were available. Serum samples were used to analyse serum
HER-2 protein, and plasma samples were used for plasma
cell-free DNA.
Of the 841 patients included in the study, 100 consecutive
patients who fulfilled the following inclusion and exclusion
criteria were selected for the circulating plasma cell-free
HER-2 DNA analyses.
Inclusion criteria:
1. Twenty-five tissue HER-2-positive patients known to
have elevated serum HER-2 protein levels;
2. Twenty-five tissue HER-2-positive patients known to
have normal serum HER-2 protein levels;
3. Twenty-five tissue HER-2-negative patients known to
have elevated serum HER-2 protein levels;
4. Twenty-five tissue HER-2-negative patients known to
have normal serum HER-2 protein levels.
Exclusion criteria: Patients without available preoperative
blood sample and patients with fewer than five blood
samples available in the follow-up.
Baseline samples were taken prior to surgery and/or
chemotherapy.
An additional 22 patients with metastases (14 tissue HER-2-
positive and eight tissue HER-2-negative), who had had a
blood sample taken after being diagnosed with metastases
and before beginning chemotherapy, were analysed with
the purpose of strengthening the results. The results from
the additional patients were evaluated together with
samples from patients with metastases from the study
population.
Fifty healthy female donors (10 aged 25–44 years, 20 aged
45–59 years, and 20 aged 60–75 years) from the control
group at the Diabetes Research Bank, Vejle Hospital, served
as healthy controls.
The work was approved by the Regional Science Ethics
Committee (reg. nr. S-VF-20040101).
2.2 Clinical Follow-up
In brief, following surgery for primary breast cancer the
patients underwent routine clinical controls at the Oncolo‐
gy Department. Patients with inoperable disease at the time
of diagnosis received neoadjuvant treatment prior to
surgery.
After surgery, the patients were treated with adjuvant
therapy according to the current guidelines from the
Danish Breast Cancer Group. Patients with tissue HER-2-
positive breast cancer determined by IHC/FISH received
Trastuzumab and/or Tykerb. Patients with tissue HER-2-
negative breast cancer received adjuvant FEC or EC
(Fluorouracil, Epirubicin, Cyclophosphamide or Epirubi‐
cin, Cyclophosphamide) and/or Docetaxel. The patients
with oestrogen-positive primary tumour received antihor‐
monal treatment.
The patients who presented symptoms of clinical recur‐
rence were further investigated. Metastases were identified
by imaging techniques with Computed Tomography/
Ultrasound/Magnetic Resonance (CT/UL/MR) and verified
by pathological examination, if possible. The levels of free-
circulating DNA and serum HER-2 did not contribute to
diagnostic decision-making.
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2.3 Laboratory Methods
2.3.1 Quantification and Validation of Cell-free Plasma HER-2
DNA
1. Samples: The patients had blood tests taken in routine
clinical controls at the Oncology Department during
the “Serum HER-2 protein project” [10]. Besides serum
samples for that project, 3 mL of peripheral blood was
also collected in an EDTA tube at each visit. The blood
was centrifuged at 2000 x g for 10 minutes within two
hours of sampling, and the plasma was divided into
two cryotubes and frozen at -80°C until analysis could
take place. We used 0.6 mL plasma/patient/visit; a few
samples had less volume, between 50 and 550 μL.
2. Purification: DNA was purified with a QIAsymphony
robot using the Qiagen Virus/Bacteria Midi Kit
(Qiagen, Hilden, Germany). The robot required 1.2 mL
volume of each plasma sample; the plasma was
therefore supplemented with water up to 1.2 ml, which
was taken into account when the results were calcu‐
lated.
3. Quantitative PCR analyses: Plasma HER-2 gene-copy
number and a reference gene-copy number were
detected by quantitative real-time PCR using in-house
assays. At the same time, we analysed CPP1 (cysteine-
rich polycomb-like protein 1), a plant gene [11] that
was added to all plasma samples with the purpose of
monitoring for loss during the purification process,
and B-cell lysis, using a peripheral-blood (PB) assay
that detects the rearranged immunoglobulin genes in
B-lymphocytes [12]. Results were excluded if they
showed signs of B-cell-lysis contamination. The HER-2
gene-copy number was calculated as 10 [(y,intercept(gHER2)
− meanCt (gHER2)) / slope(gHER2)] and the B2M gene-copy number
as 10 [(y,intercept(gB2M) − meanCt (gB2M)) / slope(gB2M)]". The plasma
volume was taken into account in the calculation of the
results.
Primers and probes for both assays were designed using
the Oligo Primer Analysis Software version 7 (Molecular
Biology Insights, Colorado, USA).
The following concentrations were used: for the B2M gene
– 3 microM forward (F) plus reverse (R) primer and 2
microM probe; for the HER-2 gene – 9 microM forward (F)
plus reverse (R) primer and 2 microM probe. Primers were
purified using a reverse-phase fast-centrifuge purification
method, while the probes were purified using an HPLC
method (DNA Technology, Aarhus, Denmark).
Primers and probe for the HER-2 gene:
F-primer: HER2ex26:64U20, 5’-GCGGTGGGGACCTGA‐
CACTA-3’
R-primer: HER2ex26:122L18, 5’-CCTTCGGAGGGTGC‐
CAGT-3’
Probe: HER2ex26:93F26, Fam-CCCTCTGAAGAG‐
GAGGCCCCCAGGTC-Tamra
Primers and probe for the B2M gene:
F-primer: B2Mex4:972U29, 5’-TAAAACT‐
TAATGTCTTCCTTTTTTTTCTC-3’
R-primer: B2Mex4:1047L27, 5’-AAACATTTTCT‐
CAAGGTCAAAAACTTA-3’
Probe: B2Mex4:387L26, Fam-CCTCCATGATGCTGCTTA‐
CATGTCTC-Tamra
The reactions were performed on ABI7900HT using 20 μl
TaqMan Universal Mastermix (Life Technologies, CA,
USA) with primers and probe and 5 μl of purified DNA
solution, as follows: initial step 50°C for two minutes and
activation step 95°C for 10 minutes, followed by 50 cycles
at 95°C for 15 seconds and 60°C for one minute. The results
are expressed in copies/mL.
All the analyses were performed in triplicate. The HER-2
gene amplification in the cell-free DNA from plasma was
determined by dividing the number of cfHER-2 DNA
copies by the number of cfB2M DNA copies.
2.4 Validation Process According to the MIQE Guidelines
2.4.1 Standard Curves
The levels of plasma cfHER-2 DNA and the reference gene
B2M were determined using standard curves calculated
with digital PCR, which is the most accurate technique for
absolute quantification. Current articles about digital PCR
analyses for HER-2 expression in breast-cancer tissue
showed good concordance with IHC/FISH [13, 14].
DNA was purified from blood from 50 healthy control
subjects and was subsequently pooled. Five microliters of
pooled DNA and subsequent five-, 25-, 125-, 625-, 3125-,
and 15,625-fold dilutions were all analysed with both
digital PCR and quantitative PCR. The results from the
digital PCR, counting a colour signal/one copy, were given
in copies/microliter. The results from the analysis on the
ABI7900HT Real-time PCR System were given in Cq.
Standard curves were drawn by matching the Cq values
with the copy number from the digital PCR. The slope for
the HER-2 standard curve was -3.43, which corresponds to
a PCR efficiency (E) of 96% where E = (10 ^ (-1/slope) -1) *
100. The slope for the B2M standard curve was -3.49,
corresponding to an efficiency of 93%.
2.4.2 Recovery Test
1.2 ml of plasma from a patient with metastatic breast
cancer was analysed on ABI7900HT.
The mean values from the triple determination were 20544
(19979, 22674, 18978) HER-2 copies/mL and 5864 (6067,
5231, 6295) B2M copies/mL. Half the portion from the initial
plasma samples (600 microliters) was mixed with water
and analysed with the following results for the mean value:
8362 HER-2 copies/mL and 2513 B2M copies/mL.
1.2 mL of plasma from the same patient was subsequently
diluted 10-fold to produce 10 samples. Each sample was
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analysed in triplicate and the average was taken as the
result of the sample. The mean values were 2153 HER-2
copies/mL (CV=7%) and 824 B2M copies/mL (CV=9%).
Each of the 10-fold dilutions was again diluted 10 times to
produce 10 samples with the following mean values: 230
HER-2 copies/mL (CV=9%) and 74 B2M copies/mL
(CV=9%). Each of the 100-fold dilutions was again diluted
10 times to produce 10 samples with the following mean
values: 21 HER-2 copies/mL (CV=19%) and seven B2M
copies/mL (CV=25%).
2.4.3 Quality Control, Reproducibility
Genomic DNA from healthy donors was used as control
material and was analysed with each master-mix. CV over
an approx. six-month period was 15% for HER-2 copy
detection and 14% for B2M copy detection.
2.4.4 Repeatability
Repeatability in the normal area was determined by
performing repeated measurements on the same sample.
20 mL of whole blood was collected from two healthy
donors. The plasma obtained from each donor was divided
into 10 portions and the DNA purified and analysed on
ABI7900HT. The first donor had a mean of 1901 HER-2
copies/mL (CV=20%) and a mean of 1621 B2M copies/mL
(CV=23%). The results from the second donor showed a
mean of 2490 HER-2 copies/mL (CV=22%) and a mean of
B2M copies/mL of 2280 (CV=17%).
2.4.5 Carry-over
DNA purification was done using the QIAsymphony
robot, which placed water samples between plasma
samples in order to detect possible cross-contamination.
No cross-contamination was detected. Water samples were
also used as a negative control for each master-mix – Non
Template Control (NTC). No positive NTCs were detected.
2.4.6 Reference Range
Reference range was determined using values from healthy
controls. Plasma from 50 healthy controls was analysed for
HER-2, B2M, CPP1 and PB. Seven controls were excluded
because of B-cell contamination. The remaining 43 healthy
controls had values between 1591 and 6252 HER-2
copies/mL (mean 3556) and 97.5 percentile 6244 HER-2
copies/mL (95%CI 5637 –6252). The values for the reference
gene B2M were between 1377 and 6019 B2M copies/mL
(mean 2923) and 97.5 percentile 5975 B2M copies/mL
(95%CI 4626–6019).
2.4.7 Analytical Sensitivity
The detection limit was determined according to a dilution
experiment where 100,000 HER-2/B2M copies from a
normal cell-line MCF10A were added to 100 microliters of
water. After analyses, repeated dilutions were performed
(first two-fold, then four-fold then 10-fold, 100-fold, 1000-
fold and 10,000-fold). The mean value for the lowest
detection limit was 40 HER-2 copies/mL (range 20–80
copies/mL; CV=42%) and 20 B2M copies/mL (range 0–20
copies/mL; CV=42%).
2.4.8 Analytical Specificity
The primers and probe ensured analytical specificity. A
blast search was performed and there were no other
predicted amplified domains. HER-2 and B2M gene
amplification products were both run in agarose gel and
each showed one band corresponding to the predicted
amplicon length (Fig. 1).
Figure 1. In gel: HER-2 gene PCR product corresponding to 76 bp and B2M
gene PCR product corresponding to 102 bp
2.4.9 Method Comparison
Page et al. used a similar method in their article about the
detection of HER-2 amplification in cfDNA from breast
cancer patients. However, they used other primers for
targeting the HER-2 gene, another reference gene
(GAPDH), and a delta Cq for determining the HER-2 gene
amplification.
2.5 Serum HER-2 Protein
Serum HER-2 was previously analysed using the ADVIA
Centaur assay, which is an automated sandwich immuno‐
assay that uses direct chemiluminescent technology and
two monoclonal antibodies specific to unique epitopes on
the extracellular domain of the HER-2 receptor [15]. Serum
HER-2 values above 15 μg/L were considered positive.
Analytical CV% in the period was determined by commer‐
cial and in-house controls at 8, 14 and 113 μg/L; the values
were 6.6, 4.6 and 4.8, respectively.
2.6 Pathological Analyses with IHC/FISH
Tissue HER-2 was routinely assessed with IHC and FISH.
IHC 3+ or IHC 2+ and FISH>2.0 were considered positive.
IHC and FISH were performed on formalin-fixed paraffin-
embedded breast-cancer tissue. IHC was analysed using
the Hercep Test (DakoCytomation, Glostrup, Denmark)
and FISH was analysed with the HER-2 FISH pharmDx kit
(DakoCytomation).
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2.6.1 Statistical Analysis
Statistical analyses were performed on STATA IC 11. A
Mann-Whitney test was used to compare two patient
groups. A Fisher-exact or chi2 test were used to compare
data from 2x2 tables.
3. Results
The characteristics of the follow-up patients are presented
in Table 1. In total, 1,142 analyses were performed on
plasma from the followed patients, with each patient
having a minimum of five samples. Eighty-five patient
samples and seven samples from the healthy controls that
were positive for PB (a sign of B-cell-lysis contamination)
were excluded from the data evaluation. Thirteen patient
samples with haemolysis were also excluded.
Age, years
<=40 1
41-50 19
51-60 31
61-70 33
>=70 16
Tissue HER-2 status
Positive 50
Negative 50
Tumour size at diagnosis (mm)
T1 40
T2 52
T3 3
T4 2
Tx 3
No. of positive nodes at diagnosis
N1 83
N2 12
N3 0
Nx 5
Metastases status at diagnosis
M0 100
Histological type
Invasive ductal
carcinoma 88
Invasive lobular
carcinoma 6
Other 5
Unknown 1
Oestrogen receptor status
Positive 69
Negative 31
Progesterone receptor status
Positive 53
Negative 44
Unknown 3
Table 1. Patient population characteristics: 100 follow-up patients
Twenty-five follow-up patients with initial primary breast
cancer developed metastatic disease in the monitoring
period. The results from the follow-up patients who
developed metastatic disease were analysed together with
the results from the additional patients with metastases.
3.1 Preoperative Plasma/serum Samples from Tissue HER-2-
positive Patients vs. Healthy Controls
Of the 50 preoperative plasma samples from patients with
tissue HER-2-positive primary tumour, seven samples
were excluded because of B-cell-lysis contamination. There
was no significant difference between preoperative plasma
cfHER-2 DNA or cfB2M DNA from tissue HER-2-positive
patients and healthy controls (Suppl. Table 1, Figure 2A).
There was no correlation between preoperative plasma
cfHER-2 DNA and the corresponding serum HER-2 protein
(range 6–52, mean 14.8, median 13 μg/L) in the tissue
HER-2-positive patient group (p=0.14).
3.2 Preoperative Plasma/serum Samples from Tissue HER-2-
negative Patients vs. Healthy Controls
Of the 50 preoperative plasma samples from patients with
tissue HER-2-negative primary tumour, four samples were
excluded because of B-cell-lysis contamination. There was
no significant difference between preoperative plasma
cfHER-2 DNA from tissue HER-2-negative patients and
healthy controls (Suppl. Table 1). The preoperative plasma
cfB2M DNA values from tissue HER-2-negative patients
were lower than the cfB2M DNA values from healthy
controls (p=0.02) (Figure 2B). There was no correlation
between preoperative plasma cfHER-2 DNA and the
corresponding serum HER-2 protein (range 6–21, mean 12,
median 11.75 μg/L) in the tissue HER-2-negative patient
group (p=0.96).
3.3 Ability of cfHER-2 DNA to Detect Metastatic Recurrence
Compared with serum HER-2 Protein
3.3.1 Samples Taken before Detection of Metastatic Disease
Compared to Patients without Metastasis (Tissue-positive
Patients)
Of the 50 tissue HER-2-positive patients, 18 patients
developed metastatic disease in the monitoring period,
while 32 remained clinically relapse-free. The plasma/
serum sample from patients with metastases was taken
within nine months of detection of symptomatic metasta‐
ses. For the patients without metastatic disease, the highest
value taken in a period without chemotherapy was chosen.
Three plasma samples from patients with metastasis were
excluded because of B-cell contamination.
There was no significant difference between the plasma
cfHER-2 DNA or cfB2M DNA values in patients before the
development of metastatic disease and those in patients
without metastasis (Suppl. Table 2). There was a significant
difference between the corresponding serum HER-2 levels
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taken before the development of metastatic disease (range
4–1729, mean 162, median 22.3 μg/L) and serum HER-2
levels in patients without metastasis (range 5–18, mean 10,
median 10.1 μg/L) (p=0.0003). In our previous work [10],
we found a good correlation between increased serum
HER-2 values and the development of metastatic disease in
tissue-positive patients.
Serum HER-2
prior to metastases detection
(tissue-positive)
With
metastases
Without
metastases
Total
Elevated 8 3 11
Normal 7 29 36
Total 15 32 47
CfHER-2 DNA
prior to metastases detection
(tissue-positive)
With
metastases
Without
metastases
Total
Elevated 8 9 17
Normal 7 23 30
Total 15 32 47
CfB2M DNA
prior to metastases detection
(tissue-positive)
With
metastases
Without
metastases
Total
Elevated 6 9 15
Normal 9 23 32
Total 15 32 47
Table 2. Number of tissue HER-2-positive patients with elevated or normal
serum HER-2, cfHER-2 DNA and cfB2M DNA levels prior to metastases
detection
We have also examined the ability of cfHER-2 DNA and
cfB2M DNA to detect metastatic recurrence compared to
serum HER-2 protein using cut-offs obtained from healthy
controls, which were 6244 HER-2 copies/mL for cfHER-2
DNA and 5975 B2M copies/mL for the reference gene B2M.
For the serum HER-2 protein, we used the known cut-off
of 15 microgram/L. The results in the tissue HER-2-positive
group showed a significant difference between the meta‐
static and non-metastatic group in the serum HER-2 protein
values (p=0.002 with a sensitivity of 53% [95%CI 27–77] and
a specificity of 90% [95%CI 73–97]) but no significant
difference for cfHER-2 DNA (p= 0.09 with a sensitivity of
53% [95%CI 27–77] and a specificity of 71% [95%CI 53–85])
or for cfB2M DNA (p=0.41 with a sensitivity of 40% [95%CI
17–67] and a specificity of 71% [95%CI 53–85]) (Table 2).
3.3.2 Samples Taken before Detection of Metastatic Disease
Compared with Patients without Metastasis (Tissue-negative
Patients)
Of the 50 tissue HER-2-negative patients, 10 patients
developed metastatic disease in the monitoring period,
while 40 remained clinical relapse-free. The plasma/serum
sample from patients with metastasis was taken within
nine months of the detection of symptomatic metastasis.
There was no significant difference between plasma
cfHER-2 DNA or cfB2M CNA in patients before the
development of metastatic disease and patients without
metastasis (Suppl. Table 3). There was no significant
difference between the corresponding serum HER-2 levels
taken before the development of metastatic disease (range
10.3–36.7, mean 17, median 14 μg/L) and serum HER-2
from patients without metastasis (range 7.3–23.4, mean 13,
median 12 μg/L) (p=0.13). In our previous article [10], we
found no correlation between increased serum HER-2
values and the development of metastatic disease in tissue-
negative patients. Using the previously specified cut-offs,
the results in the tissue HER-2-negative group showed no
difference between the metastatic and non-metastatic
group for either serum HER-2 protein (p=0.3 sensitivity of
40% [95%CI 13–72], specificity 72% [95%CI 55–84]),
cfHER-2 DNA (p= 0.1, sensitivity of 40% [95%CI 13–72],
0
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Figure 2. (a) Preoperative plasma cfHER-2 DNA and cfB2M DNA levels from tissue HER-2-positive patients compared with levels from healthy controls. (b)
Preoperative plasma cfHER-2 DNA and cfB2M DNA from tissue HER-2-negative patients compared with levels from healthy controls.
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specificity of 85% [95%CI 69–93]) or cfB2M DNA (p=0.1
with a sensitivity of 30% [95%CI 8–64], and a specificity of
90% [95%CI 75–96]) (Table 3).
Serum HER-2
prior to metastases detection
(tissue-negative)
With
metastases
Without
metastases
Total
Elevated 4 11 15
Normal 6 29 35
Total 10 40 50
CfHER-2 DNA
prior to metastases detection
(tissue-negative)
With
metastases
Without
metastases
Total
Elevated 4 6 10
Normal 6 34 40
Total 10 40 50
CfB2M DNA
prior to metastases detection
(tissue-negative)
With
metastases
Without
metastases
Total
Elevated 3 4 7
Normal 7 36 43
Total 10 40 50
Table 3. Number of tissue HER-2-negative patients with elevated or normal
serum HER-2, cfHER-2 DNA and cfB2M DNA levels prior to metastases
detection
3.4 Detection of HER-2 gene Amplification in Plasma cfDNA
cfHER-2 DNA/cfB2M DNA ratio levels had a range of 0.69–
31.88 (mean 1.95, median 1.38) in 590 follow-up samples
from 50 tissue HER-2-positive patients. Samples from the
tissue HER-2-negative patients (454) had a ratio-level range
of 0.75–2.76 (mean 1.38, median 1.34). There was a signifi‐
cant difference between the ratio levels of the tissue-
positive patients compared with those of the tissue-
negative patients (p=0.03) (Figure 3).
If a cut-off of 2.5 (which is 99 percentiles from the tissue
HER-2-negative values) was chosen, 46 (8%) samples from
the tissue HER-2-positive group had a ratio >2.5 and four
(0.9%) samples from the tissue-negative group had a ratio
>2.5.
3.5 Ratio Levels from Preoperative Samples
In the preoperative setting, there was no significant
difference between the ratio levels of the tissue HER-2-
positive patients compared with those of the tissue HER-2-
negative patients or the healthy controls (Suppl. Table 4).
One preoperative sample from the tissue HER-2-positive
group had ratio >2.5 and the same was observed for the
tissue-negative group.
3.6 Ratio Levels before Detection of Metastatic Disease
Ratio levels from samples taken within nine months before
the detection of metastatic disease in 15 tissue-positive
patients were compared with ratio levels from 10 tissue-
negative patients, but the results showed no statistically
significant difference between the two groups (Table 4).
When the results were compared with the ratio levels from
healthy controls, there was a statistically significant
difference between the ratio levels of healthy controls and
the ratio levels of tissue-positive patients (p=0.0001) but
also between the ratio levels of healthy controls and the
ratio levels of tissue-negative patients (p=0.001). Three (of
15) tissue HER-2-positive patients had ratio >2.5 prior to
metastases detection. Regarding the tissue-negative group,
none of the patients (out of 10) had ratio >2.5 prior to
metastases detection.
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Figure 3. Ratio levels of cfHER-2 DNA/cfB2M DNA in tissue HER-2-negative patients (n=454) compared to tissue HER-2-positive patients (n=590)
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Ratio
HER-2/B2M
Ratio p-value p-value
Tissue HER-2-
positive patients
(N=15)
Range 0.92–6.77 0.34 0.0001
Mean 2.26
Median 1.524
Tissue HER-2-
negative patients
(N=10)
Range 0.98–2.23 1.0 0.001
Mean 1.55
Median 1.520
Healthy controls
(N=47)
Range 0.08–1.59 1.0
Mean 1.23
Median 1.25
Table 4. Ratio between cfHER-2 DNA and cfB2M DNA prior to metastases
detection
3.7 Ratio Levels after Detection of Metastatic Disease
We also examined the ratio levels after the diagnosis of
metastatic disease prior to the start of palliative chemo‐
therapy both in the available samples from the study
population (nine tissue HER-2-positive and eight tissue
HER-2-negative patients) and in the extra samples (14
tissue HER-2-positive and eight tissue HER-2-negative
patients), in total 39 patients: 23 tissue HER-2-positive and
16 tissue HER-2-negative.
In the post-metastatic/pre-chemotherapy setting, there was
a significant difference between the ratio levels in the tissue
HER-2-positive group and those in the tissue-negative
group (p=0.01) (Table 5). In the tissue HER-2-positive
group, 11 patients had ratio >2.5 while in the tissue-
negative group none had ratio >2.5.
Ratio
HER-2/B2M Ratio p-value
Tissue HER-2-positive
patients (N=23) Range 0.9–10.7 0.01
Mean 3.55
Median 2.4
Tissue HER-2-negative
patients (N=16) Range 0.9–2.23 1.0
Mean 1.42
Median 1.4
Table 5. Ratio between cfHER-2 DNA and cfB2M DNA after metastases
detection
4. Discussion
The results gained in our study showed no difference
between the absolute preoperative cfHER-2 DNA values
for patients with primary breast cancer, regardless of tissue
HER-2 status, and absolute cfHER-2 DNA values for
healthy controls. The explanation here could be that the
tumour is localised, and that very little tumour DNA is
released into circulation. The same was observed for the
levels of the reference gene B2M, which was used to express
the total level of cfDNA in the tissue HER-2-positive group.
The results published in the literature on the levels of
cfDNA in patients with primary breast cancer are contra‐
dictory. Most studies show a higher level of total cfDNA in
plasma or serum from patients with primary breast cancer
compared with healthy controls [16-19], but others find no
difference between the two groups [20, 21]. Holdenrieder
et al. [21] found no difference in plasma cfDNA concentra‐
tions between patients with benign diseases and patients
with various types of primary cancer including breast
cancer.
One recent study [20] has investigated HER-2 gene ampli‐
fication in plasma cfDNA and the total cfDNA in patients
with primary breast cancer during neoadjuvant chemo‐
therapy. The authors found no difference in the baseline
total plasma cell-free DNA or HER-2 gene-copy number
compared to healthy controls, and no difference in baseline
plasma HER-2 gene-copy number between tissue HER-2-
positive and -negative patients; nor were they able to detect
gene amplification in plasma in the tissue HER-2-positive
patient group with primary breast cancer.
The discrepancies between cfDNA analysis results could
be explained by different sample material (serum or
plasma), different assays, or B-cell-lysis contamination. A
recent study performed at our department by Andersen et
al. [22] found plasma more suitable than serum for cfDNA
analysis. B-cell-lysis contamination may cause false
positive values. In the present study, a control assay was
used which detects rearranged genes that are only present
in lymphocytes (PB assay), and in this way it was possible
to exclude contaminated samples. Furthermore, not all the
performed studies are reported according to the MIQE
guidelines.
Regarding the patients who developed metastatic disease
in the present study, no difference was found between
cfHER-2 DNA or cfB2M DNA levels taken before (within
nine months of) the development of metastatic disease and
those taken for patients without metastases. Neither
specific cfHER-2 DNA nor the total cfDNA (reference gene
B2M) could predict the development of metastatic disease.
On the other hand, in the tissue HER-2-positive patient
group, there was a significant difference between the
corresponding serum HER-2 protein levels before recur‐
rence developed and those for patients without recurrence.
The difference in the tissue-negative group was not
significant. This agrees with the previous work on serum
HER-2 protein [10], where a high correlation was found
between the increase in serum HER-2 and metastatic
recurrence for tissue-positive patients, though the correla‐
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tion was not significant for the tissue-negative group after
adjustment for confounders with a logistic regression
analysis.
Regarding the HER-2 gene amplification in plasma, the
ratio between cfHER-2 DNA and the reference gene cfB2M
DNA was significantly higher in the tissue HER-2-positive
group compared with the tissue-negative group when all
the patient values were used. The values after the devel‐
opment of metastasis could also be useful in a clinical
setting in order to differentiate between HER-2-positive
and -negative disease, since it is known that amplification
status is not always the same in metastatic tissue as in the
primary tumour. After the development of metastatic
disease and prior to start of treatment, there was a signifi‐
cant difference between the ratio levels in the tissue HER-2-
positive group and those in the tissue-negative group.
Others have examined the same issue. Page et al. [8] found
amplification in cfDNA in eight out of 68 patients following
treatment for primary breast cancer and also in five out 30
patients with metastatic disease, but not in 22 patients with
primary breast cancer. Bechmann et al. [20] included 15
patients with diagnosed metastatic disease (nine tissue
HER-2-positive and six tissue HER-2-negative) in their
study and found significantly higher plasma HER-2
amplification in the tissue-positive group compared to
healthy controls, but not for the tissue-negative group.
Sorensen et al. [9] found plasma HER-2 amplification in
50% (14 of 28) of patients with tissue HER-2-positive
metastatic breast cancer using a cut-off value of 2xSD above
the mean of the controls.
5. Conclusion
We conclude that in our population, neither absolute
values of specific cfHER-2 DNA nor the total cfDNA
(reference gene B2M) could discriminate between patients
with primary breast cancer and healthy controls, or predict
the development of metastatic disease. Amplified HER-2
DNA can be detected in plasma, mostly in the tissue-
positive group and after the diagnosis of metastatic disease.
More studies are needed in order to validate the usefulness
of detection of amplified cfHER-2 DNA in plasma from
breast cancer patients. Improvement of the method of
detection of cell-free DNA could facilitate interpretation of
results and increase both the sensitivity and the specificity
of the analysis. In our population, with the current meth‐
ods, serum HER-2 protein seems more sensitive and
reliable in detecting metastatic recurrence than cell-free
DNA.
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